BlackRock Health Sciences Opportunities Portfolio Service Shares
SHISX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Bellevue Parkway Wilmington DE United States of America 19809
- IPO Date
- Jan 28, 2005
- CIK
- 0000844779
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Opportunities Portfolio Service Shares (SHISX) is a mutual fund that seeks long-term growth of capital by investing at least 80% of its total assets in equity securities, primarily common stocks, of companies in health sciences and related industries; these include health care equipment and supplies, health care providers and services, biotechnology, pharmaceuticals, life sciences tools and services, as well as businesses involved in the development, production, distribution, and delivery of medical and pharmaceutical products, medical research and development, diagnostic equipment and services, and health facilities or hospitals. The fund concentrates more than 25% of its assets in these sectors, holds companies of varying market capitalizations without limitation, and may invest in non-U.S. issuers; up to 20% of assets may be allocated to other securities, such as stocks outside health sciences, convertible securities, depositary receipts, derivatives for hedging or return enhancement, or money market instruments for liquidity. Headquartered at BlackRock Advisors, LLC in New York, NY, with key operations in the United States and exposure to global markets, the Service Shares class (ticker: SHISX) was launched on January 28, 2005; the fund is managed by portfolio managers Erin Xie, PhD (since 2003) and Xiang Liu, PhD (since 2020). As of May 31, 2025, the fund's net assets stand at approximately $6.45 billion, with 131 holdings and a portfolio turnover rate of 43%; top holdings include Eli Lilly & Co. (8.9%), Boston Scientific Corp. (6.7%), AbbVie Inc. (6.0%), Abbott Laboratories (5.4%), and UnitedHealth Group Inc. (4.4%), representing key exposures in pharmaceuticals (24.9%), health care equipment and supplies (29.1%), biotechnology (20.5%), and health care providers and services (15.2%). In the latest annual period ended May 31, 2025, the fund delivered a total return of -6.08% for Service Shares, underperforming the Russell 3000 Index (13.12%) but aligning closely with the Russell 3000 Health Care Index (-6.31%); performance contributors included strong gains from Boston Scientific Corp., Abbott Laboratories, and Gilead Sciences Inc., driven by revenue growth, earnings beats, and positive clinical data, while detractors were led by UnitedHealth Group Inc. due to rising medical costs, CEO transition, withdrawn guidance, and a DOJ probe, alongside Eli Lilly & Co. and Thermo Fisher Scientific Inc. from earnings shortfalls and macroeconomic pressures. The fund maintained its core strategy with no reported major structural changes, such as acquisitions, partnerships, funding rounds, or new product launches; BlackRock continues contractual management fee waivers through June 30, 2026, for certain embedded fund investments and money market fees, supporting a net expense ratio of 1.15%. Recent portfolio adjustments reflect active management amid sector volatility, with ongoing emphasis on health sciences amid technological advancements and regulatory dynamics.